Research  >  Research  >  Research platforms  >  Evaluative Clinical Sciences  >  Scientists
PAGE
MENU

Evaluative Clinical Sciences

SRI platforms

Lorne Zinman, MD, M.Sc., FRCPC

Associate scientist

Sunnybrook Health Sciences Centre
2075 Bayview Ave., Room UG 26
Toronto, ON
M4N 3M5


Administrative Assistant: Olive Grozelle
Phone: 416-480-4213
Fax: 416-480-6817

Education:

  • B.Sc., 1993, biology/physiology (with distinction), University of Toronto, Canada
  • M.Sc., 1995, neurobiology, Queen’s University, Canada
  • MD, 1998, University of Calgary, Canada
  • FRCPC, 2003, neurology, U of T, Canada
  • Neuromuscular diseases fellowship, 2005, U of T, Canada
  • M.Sc., 2005, clinical epidemiology, U of T, Canada

Appointments and Affiliations:

  • Associate scientist, Evaluative Clinical SciencesHurvitz Brain Sciences Research Program, Sunnybrook Research Institute
  • Staff neurologist, Sunnybrook Health Sciences Centre
  • Director, neurophysiology lab, Sunnybrook
  • Associate professor, Institute of Medical Science and Rehabilitation Sciences Institute, U of T
  • Director, ALS and neuromuscular clinic, Sunnybrook

Research Focus:

  • Amyotrophic lateral sclerosis and neuromuscular diseases

Research Summary:

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a devastating neurological disease that results in the degeneration of motor neurons leading to paralysis and death in most patients. There is no treatment to halt or reverse ALS, and its specific cause remains unknown. Dr. Zinman’s research aims to characterize better the clinical, electrophysiological and pathological phenotypes and variants of the disease to find a treatment.

In collaboration with Drs. Janice Robertson, Ekaterina Rogaeva, Yana Yunusova and Julia Keith, the group is studying the disease’s pathophysiology to discover novel therapeutic targets. Epidemiological research provides clues to the etiology and exacerbating factors of the disease. The team also leads and participates in multicentre clinical trials evaluating the most promising ALS therapeutics. Dr. Zinman is the founder and first chair of the Canadian ALS Research Network. Its primary purpose is to find new treatments and improve the lives of people with ALS.

Selected Publications:

See current publications list at PubMed.

Related News and Stories:

Related Links: